These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35046733)

  • 21. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
    Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
    de Llano LP; Naval E; Mejía N; Domínguez-Ortega J
    Expert Rev Respir Med; 2022 Jan; 16(1):1-15. PubMed ID: 34783265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial.
    Beier J; Watz H; Diamant Z; Hohlfeld JM; Singh D; Pinot P; Jones I; Tillmann HC
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 33898609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β
    Niimi A; Kanemitsu Y; Tajiri T; Sumi K; Mikami T; Kondo N
    ERJ Open Res; 2023 Mar; 9(2):. PubMed ID: 37009022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
    Blair HA
    Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
    Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
    Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
    Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma.
    Jabbal S; Manoharan A; Lipworth BJ
    Clin Exp Allergy; 2017 Oct; 47(10):1239-1245. PubMed ID: 28665534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of the month : FLAME study in chronic obstructive pulmonary disease].
    Corhay JL
    Rev Med Liege; 2016 Sep; 71(9):400-406. PubMed ID: 28383836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corrigendum to "Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)" [Respir. Med. 170 (Aug-Sep 2020) 106021].
    Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
    Respir Med; 2020 Dec; 175():106186. PubMed ID: 33082033
    [No Abstract]   [Full Text] [Related]  

  • 37. Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma.
    Karpel JP; Nelson H
    Curr Med Res Opin; 2007 Nov; 23(11):2897-911. PubMed ID: 17922978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea.
    Lee SH; Rhee CK; Yoo K; Park JW; Yong SJ; Kim J; Lee T; Lim SY; Lee JH; Park HY; Moon M; Jung KS
    Tuberc Respir Dis (Seoul); 2021 Apr; 84(2):96-104. PubMed ID: 33352035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis.
    Zhang Q; Zhang H; Wang J; Ruan Z; Dai Y; Xia Z; Lv Q
    Heart Lung; 2021; 50(4):532-541. PubMed ID: 33865004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.